Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p.m. East...
April 29 2021 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a clinical-stage biopharmaceutical company dedicated to
the development of cellular therapies designed to reverse disease,
today announced that the Company will report its financial results
for the three months ended March 31, 2021 on Thursday, May 6, 2021
at 4:30 p.m. (ET). To join the live conference call, please refer
to the dial-in information provided below.
Dial-in information: U.S. Toll-Free:
866-595-8403International:
706-758-9979Conference ID / Access code:
6892792
A live webcast of the call will be available on the Caladrius
website under the Investors & News section. A replay of the
webcast will also be available for 90 days following the conclusion
of the call.
For those unable to participate on the live conference call, an
audio replay will be available that day starting at 7:30 p.m. (ET)
until May 13, 2021, by dialing 855-859-2056 (North America) or
404-537-3406 (International) and by entering the access code:
6892792.
About Caladrius Biosciences
Caladrius Biosciences, Inc. is a clinical-stage
biopharmaceutical company dedicated to the development of cellular
therapies designed to reverse disease. We are developing
first-in-class cell therapy products based on the finely tuned
mechanisms for self-repair that exist in the human body. Our
technology leverages and enables these mechanisms in the form of
specific cells, using formulations and modes of delivery unique to
each medical indication.
The Company’s current product candidates include: CLBS16, the
subject of both a recently completed positive Phase 2a study and a
newly initiated Phase 2b study in the U.S. for the treatment of
coronary microvascular dysfunction (“CMD”); HONEDRA® (CLBS12),
recipient of orphan designation for Buerger’s Disease in the
U.S. as well as SAKIGAKE designation and eligible for early
conditional approval in Japan for the treatment of critical limb
ischemia (“CLI”) and Buerger’s Disease based on the results of an
ongoing clinical trial; CLBS201, designed to assess the safety and
efficacy of CD34+ cell therapy as a treatment for diabetic kidney
disease (“DKD”); and OLOGO™ (CLBS14), a Regenerative Medicine
Advanced Therapy (“RMAT”) designated therapy for which the Company
is in discussion with the FDA to finalize a Phase 3 protocol of
reduced size and scope for a confirmatory trial in subjects with
no-option refractory disabling angina (“NORDA”). For more
information on the Company, please
visit www.caladrius.com.
Contact:
Investors:Caladrius Biosciences, Inc.John MendittoVice
President, Investor Relations and Corporate
CommunicationsPhone: +1-908-842-0084Email: jmenditto@caladrius.com
Media: Real ChemistryKelly WakeleePhone: 610.639.2774Email:
kwakelee@realchemistry.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024